 Fulgent Genetics Inc NASDAQ: FLGT reported after the close of the market on Monday that its second-quarter revenues increased nearly ninefold, driven primarily by increased test volumes. Revenues skyrocketed to 153.6 million from 17.3 million in Q2 of 2020 but missed the consensus of 197.3 million. 